

**TROPICAL DISEASE
FOUNDATION, INC.**

2023-2024 ANNUAL REPORT



www.tdf.org.ph



TROPICAL DISEASE FOUNDATION, INC.

ABOUT TDF

The Tropical Disease Foundation, Inc. (TDF) is a non-profit organization established in 1984 by a group of physicians from the Research Institute for Tropical Medicine.

Led by its founding chairman and former Secretary of Health, Dr. Jesus Azurin, TDF committed to excellence in research, service, and training.

Since its inception, TDF has been at the forefront of pioneering initiatives in fighting tropical diseases, leaving an indelible mark on the landscape of public health.

MISSION

National and local community development through research, training, service, and healthcare delivery in the prevention and control of infectious diseases of public health importance.

VISION

Equitable universal access to health for national prosperity.

THRUSTS



To conduct research, training and service in infectious diseases of public health importance.



To enter into partnership with public and private agencies in the implementation of programs in the control of infectious diseases.



To ensure technology transfer in developing human resources for health nationally and internationally through collaboration with national and international institutions.



To serve as a national and international training center for infectious diseases.

LETTER FROM THE EXECUTIVE DIRECTOR



Dear Friends,

Stepping up during critical times is as important as being steadfast in our commitment to our organizational priorities. Three years ago, by leveraging on the inherent strength of our organization, we embarked on scaling up our operations with new programs and approaches that use innovative tools, products, and technologies to deliver high-impact key results to our beneficiaries. As a major part of our strategy for expansion and growth, we created more partnerships with other nonprofits and social change organizations which enabled other intermediaries and groups to offer high-impact and integrated projects and programs through research, service delivery, training, and sharing best practices.

Though we cannot be confident of what the future holds, we can always be clear and resolved in our mission, the eradication of infectious diseases of public health importance as one of the keys for national prosperity. We embody the trademark of optimism we shared with our Founder, Dr. Thelma E. Tupasi, and in her belief that a better and healthier world is possible through our shared vision, values, and actions.

We are like the trees in a forest that tell their story via rings. The first ring is a beginning with subsequent rings celebrating growth. The spaces between the rings explain how this growth happened. By leveraging on the talents and resources of the public, private and philanthropic sectors, we did what no one of us could achieve alone. By uniting the passion and commitment of our donors, partners, advisors, community leaders and stakeholders, we created sustainable solutions that will continue to affect lives for years to come.

This year's Annual Report highlights how we worked towards long-term solutions to the problems of TB and HIV in the country, while continuing to provide relief to the current needs of the patients accessing the services we offer. As we work, we grow, we learn, we adapt and we innovate. Our partners made our tree ring grow wider and deeper.

Thank you for your many compassionate actions, support, partnership, and friendship over the years. I remain grateful, humbled, and inspired.

JULIUS A. LECCIONES, MD, PHD, DPA

Executive Director



TABLE OF CONTENTS

RESEARCHES

01

TRAININGS

14

SERVICES

34

PROJECT HIGHLIGHTS

40

COMMUNITY ENGAGEMENTS

56

PARTNERSHIPS

65

FINANCIAL SUMMARY

70


OUR TEAM

78





TROPICAL DISEASE FOUNDATION, INC.



RESEARCHES



LG-VCCCL002

Principal Investigator: Dr. Maria Rosario Z. Capeding

A Phase 3b trial that evaluated the safety, one-year antibody persistence, and immune response of **Eupolio Injection** (inactivated polio vaccine using Sabin strains) in infants after three doses. This multicenter, open-label, interventional study also assessed the effect of giving two doses of Eupolio after three doses of oral polio vaccine (bOPV).

OVERVIEW

Sponsor:
LG Chem, Ltd

Target Reach:
42-56 days infants

Area of Coverage:
Makati City

Period of Coverage:
March 2023 – May 2024

UPDATES

Ethics Committee Initial Approval: February 13, 2023

Site Initiation Visit: March 1, 2023

Start of Enrollment: March 10, 2023

End of Enrollment: April 5, 2023

Total Enrolled: 155

Study Status: Completed



Medical Research Unit Clinical Trial Team



64281802DNG2004

Principal Investigator: Dr. Maria Rosario Z. Capeding

A Phase 2 trial that assessed the safety and effectiveness of two doses of **JNJ-64281802** in preventing **dengue** infection. The study was randomized, double-blind, placebo-controlled, double-dummy, and multicenter.

OVERVIEW

Sponsor:
Janssen Research & Development, LLC

Target Reach:
18 – 65 years old

Area of Coverage:
San Pablo City, Laguna

Period of Coverage:
April 2023 – April 2025

UPDATES

Ethics Committee Initial Approval: July 5, 2022

Site Initiation Visit: April 18, 2023

Start of Enrollment: June 1, 2023

End of Enrollment: March 24, 2024

Total Enrolled: 37

Study Status: Closed



San Jose Clinical Trial Team



YS-002

Principal Investigator: Dr. Maria Rosario Z. Capeding

A Phase 3 trial that evaluated the effectiveness, safety, and consistency of the **PIKA Rabies Vaccine (Vero cell)** in healthy adults aged 18–65. The freeze-dried vaccine was given as post-exposure protection after possible rabies exposure. The study was randomized, double-blind, and conducted across multiple sites.

OVERVIEW

Sponsor:
Yisheng Biopharma (Singapore) PTE. LTD.

Target Reach:
18 – 65 years old

Area of Coverage:
San Pablo City, Laguna

Period of Coverage:
1 year

UPDATES

Ethics Committee Initial Approval: April 14, 2023

Site Initiation Visit: August 25, 2023

Start of Enrollment: October 13, 2023

End of Enrollment: October 25, 2023

Total Enrolled: 505

Study Status: Completed



San Pablo City Clinical Trial Team



COVENT-202

Principal Investigator: Dr. Maria Rosario Z. Capeding

A Phase 3 trial to evaluate the safety and effectiveness of the **AdCLD-CoV19-1 OMI** COVID-19 booster vaccine in adults aged 19 and older. This study is multicenter, observer-blinded, randomized, active-controlled.

OVERVIEW

Sponsor:
Cellid Co., Ltd

Target Reach:
19 years old and above

Area of Coverage:
Alaminos, Laguna

Period of Coverage:
18 months

UPDATES

Ethics Committee Initial Approval: February 2, 2024

Site Initiation Visit: August 21, 2024

Start of Enrollment: August 27, 2024

End of Enrollment: October 31, 2024

Total Enrolled: 684

Study Status: Follow-up Phase



Alaminos, Laguna Clinical Trial Team



LG-VGCL002

Principal Investigator: Dr. Maria Rosario Z. Capeding

A Phase 2 trial to assess the safety and effectiveness of **LR20062 hexavalent vaccine** compared to Hexaxim in healthy infants. The vaccine was given as a primary series at 2, 4, and 6 months of age.

OVERVIEW	UPDATES
<i>Sponsor:</i> LG Chem, Ltd <i>Target Reach:</i> 2 months old <i>Area of Coverage:</i> Muntinlupa City <i>Period of Coverage:</i> 1 year	<i>Ethics Committee Initial Approval:</i> July 24, 2024 <i>Site Initiation Visit:</i> October 2, 2024 <i>Start of Enrollment:</i> October 4, 2024 <i>End of Enrollment:</i> December 21, 2024 <i>Total Enrolled:</i> 123 <i>Study Status:</i> Follow-up Phase



Muntinlupa City Clinical Trial Team



KD414-03

Principal Investigator: Dr. Edison R. Alberto

A Phase 3 trial that compared the immunogenicity, efficacy, and safety of the **Kd414-03** and **Vaxzevria COVID-19 vaccines** in adults aged 18 to 40. It's randomized, double-blind, active-controlled, multicenter, and confirmatory.

OVERVIEW

Sponsor:
Meiji Seika Pharma Co., Ltd.

Target Reach:
18-40 years old

Study sites: Japan, 4 in the Philippines and one of them is Health Index Multispecialty and Lying-in Clinic (HIMC) in Mambog, Bacoor, Cavite

Period of Coverage:
1 year

UPDATES

Site Initiation Visit: July 7, 2022

Start of Enrollment: November 24, 2023

End of Enrollment: February 7, 2024

Total Enrolled: 191

Study Status: Close-Out



Close-Out Visit



PRO-QINF-3004

Principal Investigator: Dr. Charissa Tabora

A Phase 3 trial that evaluated the immunogenicity and safety of **Sinovac's inactivated quadrivalent Influenza vaccine (Split Virion)** in individuals aged 3 years and older, compared to the licensed vaccine VaxigripTetra. It's randomized, double-blind, and controlled.

OVERVIEW

Sponsor:
Sinovac Biotech Co., Ltd

Target Reach:
3 years and above

Area of Coverage:
Muntinlupa

Period of Coverage:

UPDATES

Ethics Committee Initial Approval: February 5, 2023

Site Initiation Visit: April 19, 2023

Start of Enrollment: May 9, 2023

End of Enrollment: June 10, 2023

Total Enrolled: 451

Study Status: Completed



PRO-QINF-3004 SIV Training



C4781004

Principal Investigator: Dr. Charissa Tabora

A Phase 3 trial that evaluated the efficacy, safety, tolerability, and immune response of a **modified RNA influenza vaccine** compared to a licensed inactivated flu vaccine in healthy adults aged 18 and older. The study was randomized, observer-blind, and multicenter.

OVERVIEW

Sponsor:
Pfizer

Target Reach:
65 years old and above

Area of Coverage:
Muntinlupa

Period of Coverage:
6 months

UPDATES

Ethics Committee Initial Approval:

Site Initiation Visit: July 7, 2023

Start of Enrollment: August 3, 2023

End of Enrollment: August 16, 2023

Total Enrolled: 400

Study Status: Completed



C4781004 SIV Training



YS-002

Principal Investigator: Dr. Charissa Tabora

A Phase 3 trial that assessed the immune response, safety, and consistency of three batches of the freeze-dried **PIKA rabies vaccine** in healthy adults following a post-exposure treatment schedule. The study is randomized, double-blind, comparator-controlled, and conducted across multiple centers.

OVERVIEW

Sponsor:
Yisheng Biopharma

Target Reach:
18 year old and above

Area of Coverage:
Muntinlupa

Period of Coverage:
1 year

UPDATES

Ethics Committee Initial Approval: April 23, 2023

Site Initiation Visit: August 31, 2023

Start of Enrollment: October 14, 2023

End of Enrollment: October 25, 2023

Total Enrolled: 556

Study Status: Completed



YS-002 SIV Training



ARCT2303-01

Principal Investigator: Dr. Charissa Tabora

A Phase 3 trial that evaluated the immunogenicity, safety, and side effects of the self-amplifying **RNA COVID-19 vaccine ARCT-2303**, given at the same time as a quadrivalent influenza vaccine in adults. It's multicenter, randomized, controlled, and observer-blind.

OVERVIEW	UPDATES
<i>Sponsor:</i> Arcturus Therapeutics, Inc. <i>Target Reach:</i> 18 years old and above <i>Area of Coverage:</i> Muntinlupa, Paranaque <i>Period of Coverage:</i> 6 months	<i>Ethics Committee Initial Approval:</i> January 16, 2024 <i>Site Initiation Visit:</i> April 19,2024 <i>Start of Enrollment:</i> April 22,2024 <i>End of Enrollment:</i> May 31, 2024 <i>Total Enrolled:</i> 288 <i>Study Status:</i> Completed



ARCT-2303-01 SIV Training



GATES MRI TBV02-E01

An epidemiologic study that determined the proportion of individuals who test positive using the **Interferon-Gamma Release Assay (IGRA)** in places where TB is common. The study also serves to strengthen local research capacity in preparation for a pivotal Phase 3 clinical trial evaluating TB vaccine efficacy.

The results are not meant to show the overall number of people with latent TB.

OVERVIEW

Period of Coverage: August 1, 2023 – July 31, 2024

Area of Coverage: Makati, Manila and Pasay Cities

Site Initiation Visit: July 25, 2022

Site Recruitment Activation: August 17, 2022

Completed Target Recruitment: October 17, 2022

Completed Month 12 Visit: 155/160 (96.8%)

Study Status: Closeout January, 2025



GATES MRI TBD06-201

A Phase 2b/c multi-arm, two-stage randomized trial to assess shorter treatment regimens for adults with drug-susceptible pulmonary tuberculosis (TB).

It evaluates the safety, tolerability, and effectiveness of combinations including **Bedaquiline**, **OPC-167832**, **Sutezolid**, and either **Pretomanid** or **Delamanid**, aiming to shorten the standard 6-month TB treatment to 2 to 4 months.

OVERVIEW

Period of Coverage: August 1, 2023 – October 31, 2024

Area of Coverage: Makati, Manila and Pasay Cities

Site Initiation Visit: November 9, 2023

Site Recruitment Activation: November 17, 2023

Completed Target Recruitment: July 13, 2024

Total Enrolled: 2 (6 Screen Failed)



NC-009

A Phase 2, partially blinded, randomized trial to evaluate the safety and effectiveness of TBAJ876 or **Bedaquiline**, combined with **Pretomanid** and **Linezolid**, in adults with newly diagnosed drug-sensitive, smear-positive pulmonary tuberculosis (TB).

The goal is to see if the new treatments, TBAJ876 (administered in three doses) or Bedaquiline, combined with Pretomanid and Linezolid, offer improved outcomes while remaining safe and well-tolerated for patients.

OVERVIEW

Period of Coverage: August 1, 2023 – October 31, 2024

Area of Coverage: Makati, Manila and Pasay Cities

Site Initiation Visit: February 8, 2024


Site Recruitment Activation: February 27, 2024

Total Enrolled: 5 (3 Screen Failed)





TROPICAL DISEASE FOUNDATION, INC.



TRAININGS

INE CONFERENCE
10, 2023

ASIAN VACCINE
CONFERENCE
ASAC 2023

24TH PHILIPPINE NATIONAL IN
NOVEMBER 1



MAKATI MEDICAL CENTER FELLOWSHIP ROTATION PROGRAM

The Training Program, in collaboration with the Infectious Diseases and Pulmonology Departments of Makati Medical Center (MMC), provides fellows with hands-on experience in TB clinical management and laboratory assessments.

Fellows participate in 1-2 month rotations, gaining exposure to TB diagnosis, treatment, and laboratory procedures.

Since its launch in September 2014, the program has trained **12** fellows during the current year.

OVERVIEW

Period of Coverage: August 1, 2023 – July 31, 2024

Cooperating Agency: Makati Medical Center

Target Reach: Makati Medical Center Infectious Diseases and Pulmonology Fellows



TB IN THE WORKPLACE PROMOTION

September 14, 2023

The TB Clinic was invited by Electrical Equipment and System Integration (EESI), Inc. to lead a “TB in the Workplace” session for its employees.

EESI is a comprehensive electrical engineering and contracting company offering services ranging from engineering and construction to fabrication, training, quality management, and maintenance.

The session was conducted in a hybrid format, with employees attending both in person and remotely via Google Meet, allowing participation from multiple branches.



ASIAN VACCINE CONFERENCE

November 2023

The 9th Asian Vaccine Conference (ASVAC 2023) was held in Cebu, Philippines, from November 8–11, 2023 with over 1,000 global participants.

The event covered key topics such as

- global vaccinology,
- COVID-19 updates,
- pandemic preparedness, and
- vaccine development.

Highlights included a Vaccinology Masterclass, EPI Managers' Meeting, and the Philippine National Immunization Conference.

Public health experts, researchers, and industry leaders joined to exchange knowledge and strengthen collaboration for the future of immunization in Asia and beyond.



PHILIPPINE NATIONAL IMMUNIZATION CONFERENCE

November 2023

The 24th PNIC was held on November 11, 2023, in Cebu City, as part of a back-to-back event with the 9th Asian Vaccine Conference (ASVAC).

The conference focused on vaccine efficacy, safety, and the critical role of immunization in public health.

Key topics included the role of HPV vaccines in preventing cervical cancer and strategies to address vaccine misinformation and hesitancy.



TRAINING OF TRAINERS

Key Updates to the Current Drug-Resistant Tuberculosis Treatment (BPAL/M)

As part of the ongoing rollout of the Integrated Delivery of TB Services (iDOTS) Strategy, the Tropical Disease Foundation – iDOTS Coordinating Center was invited to participate in the Training of Trainers organized by the Department of Health Metro Manila Center for Health Development (DOH-MMCHD).

The training took place from March 19 to 22, 2024 at the Winford Manila Resort Hotel.

The event brought together members of the Regional TB Medical Advisory Committees, providing them with the opportunity to learn and develop the skills necessary to implement and share the newly available DRTB regimens across the country.



PEER-TO-PEER LEARNING FOR INNOVATIVE CURES

Launched on World TB Day (March 2024), **PeerLINC** is a global knowledge hub that promotes peer-to-peer learning to accelerate the use of innovative, effective tuberculosis treatments.

PeerLINC provides training, materials, tools, best practices, learning and experience on five key areas of the new TB treatment rollout:

- **Clinical management**, including active TB drug safety monitoring (aDSM)
- **Programmatic implementation**, such as cost-effectiveness
- **Laboratory support**
- **Community engagement**, focusing on people-centered TB care
- **GEDSI** – Gender Equality, Disability, and Social Inclusion

PeerLINC is hosted by the Tropical Diseases Foundation, Inc. in close collaboration with the Department of Health and supported by TB Alliance.



TB Alliance



PEER-TO-PEER LEARNING FOR INNOVATIVE CURES



Records Review during Field Visit

The training is led by a team of experts with direct experience in TB treatment and includes case studies, clinic and lab visits, and ongoing mentoring to support country implementation of new regimens.

PeerLINC aims to grow as a platform for broader learning on TB and other infectious diseases, helping build stronger systems for disease response and pandemic preparedness.



Country Planning




PEER-TO-PEER LEARNING FOR INNOVATIVE CURES

ACCOMPLISHMENTS

COUNTRY	TIMELINE	VENUE	SUPPORT PROVIDED
Peru	April 1-5, 2024	Philippines	Full Training
Rwanda	April 22, 29-30, 2024	Zoom	Guidelines
DRC	July 1-5, 2024	Philippines	Full Training
Nigeria	July 30 – August 1, 2024	Nigeria	Clinical Training



Peru



DRC



Nigeria



PeerLINC Team



WORLD IMMUNIZATION WEEK TRAINING FOR MUNTINLUPA BHWS

April 2024


During World Immunization Week 2024 (April 24–30, 2024), the City of Muntinlupa participated in global activities to promote the importance of vaccines in preventing diseases.

One notable event was a Basic Vaccinology Training for Muntinlupa's Barangay Health Workers (BHWs), where Dr. Charissa Tabora served as one of the lecturers. Her clinical trial staff volunteered as facilitators, helping make the activity a success.




HIV COUNSELLING TO TESTING (HCT) TRAINING

June 25-28, 2024




HIV COUNSELLING TO TESTING (HCT) TRAINING

June 25–28, 2024



SYNDROMIC STI MANAGEMENT TRAINING

July 2-5, 2024



INTERNATIONAL CONFERENCES IN HIV & AIDS

TDF actively participated in the **Young People First! Regional Conference on Humanization of Healthcare and Young Key Populations**, organized by EpiC-HIV Project Thailand, IHRI, and Youth Lead.

Represented by Mr. Welmar Cruel, TDF reinforced its commitment to advancing healthcare access and equity for young key populations (YKP) affected by HIV.



Mr. Welmar R. Cruel – Peer Navigator attended the Regional Conference for Asia and the Pacific Region on Humanization of Healthcare and Young Key Populations held in Bangkok, Thailand.



SUMMARY OF TRAININGS

EMPLOYEE	TRAINING	DATE / VENUE
1. FONDALES, ABIGAIL N.	In - Depth Information Seminar	August 14 - 15, 2023 / Online
2. CATINDIG, ANGELITO M.	Maximizing the Use of MS Excel Functionalities in Conducting Audit Techniques	August 17, 2023 / Online
3. CATINDIG, ANGELITO M.	Estate Tax And Estate Tax Amnesty	August 23, 2023 / Online
4. CATINDIG, ANGELITO M.	Internal Control and Fraud Prevention	August 25, 2023 / Online
5. BALANE, GLENN BALIWAGAN, MA. BEGONIA R. BAUZON, PHOEBE HANNAH CABANATAN, MA. LOURDES O. CAINONG, JOHN OSMOND CARIDAD, MA. TERESA A. CATINDIG, ANGELITO M. CRUEL, WELMAR DE GUZMAN, ALBERTO E. JR. DELA TORRE, MARK AARON EDUARDO, MARISSA E. EDUARDO, MARISSA E. FONDALES, ABIGAIL N. GERONIMO, ANTHONY A. HERNANDEZ, GLAIZA ERIKA KIHOM, HARLEY RONNIEKSON	Microsoft Office Training	August 29 - 31, 2023 / Tiara Hotel, Makati



SUMMARY OF TRAININGS

EMPLOYEE	TRAINING	DATE / VENUE
MENDOZA, JAYPEE ALBERT MONTON, ROGESELLE B. NUCUM, MARITA I. OCAMPO, CAMILLE PERENA, MHON ADRIAN PUYOT, KIM OLIVER REYES, EMMANUEL ROQUE, RENATO ROWAN, RHANDY R. TOLENTINO, CELESTINE JOY TORREDA, JOELYN B. TORRES, ROCHELLYN VETO, DR. RHOLINE GEM MARTIN VILLAMINA, ELMA	Microsoft Office Training	August 29 - 31, 2023 / Tiara Hotel, Makati
6. MENDOZA, JAYPEE ALBERT	HIV Counseling to Testing Training	September 4 - 6, 2023 / Madison 101 Hotel
7. BAUZON, PHOEBE HANNA DC.	Consultative Workshop for the Regional Laboratory Response Network	September 12, 2023 / Ciudad Christina Resort, San Mateo
8. KIHOM, HARLEY RONNIEKSON	Procurement and Supply Chain Management Training	October 22 - 27, 2023 / Jade Hotel, Makati
9. GARCIA, KATHLEEN GRACE T.	National HIV Treatment Hub Conference 2023	November 27 - 30, 2023 / Heritage Hotel



SUMMARY OF TRAININGS

EMPLOYEE	TRAINING	DATE / VENUE
10. GERONIMO, ANTHONY A. BENAVENTE, MAITA B. DELA CRUZ, ELSIE MARIE HERNANDEZ, GLAIZA ERIKA ESGUERRA, SOPHIA CELINE CAMARA, ZACHARIE LOU CRUZ, KIRK MARTIN DELA CRUZ, JOANER PAOLO DEOCARIS, KRISTIN MAY MONDEJAR, GABRIEL SALARDA, WYETH KEVIN LOBO, SEAN MARTIN GODSON VALENTINO, PRISCILLA MENDOZA, ANGELA MARIE CARNALNA, ANGELA MARIE RARUGAL, JUSTIN MIGUEL PULMINAR, REALYN EVANGELISTA, TRISTAN NICOLE CUENO, KARL FRANCIS LEPITEN, CHRISTIAN BALEROS, BENJIE CAMPOLLO, DOMINGO	DAIDS Good Clinical and Laboratory Practices	November 20-22, 2023 / Sheraton Manila Bay
11. BAUZON, PHOEBE HANNA DC.	GeneXpert HIV Viral Load Assay	December 20, 223 / Online



SUMMARY OF TRAININGS

EMPLOYEE	TRAINING	DATE / VENUE
12. FERIDO, MARK A. ATIENZA, RANDY S. ROXAS, LUISITO JR. T. CUSO, RONALD GARCIA, KATHLEEN GRACE T. BALMEO, JULIA ELOSE CABIGAO, MA. ANDREA KEISHA	HIV Counseling to Testing	January 15 - 17, 2024 / Madison 101 Hotel
13. ROXAS, LUISITO T. JR.	Community-Based HIV Screening	January 18 - 20, 2024 / Madison 101 Hotel
14. MONTON, ROGESELLE B. KIHOM, HARLEY RONNIEKSON REYES, EMMANUEL FERIDO, MARK A. ATIENZA, RANDY S. DARJUAN, RONALD E. RAMIREZ, JOHN ENRIQUE A. BAUZON, PHOEBE HANNAH TORRES, ROCHELLELYN L. OCAMPO, CAMILLE TOLENTINO, CELESTINE JOY P.	TB Preventive Treatment and OHASIS Training	February 19 - 22, 2024 / Jade Hotel, Makati
15. UBALDE, JOHN PHILLIP C.	Abstract Writing 101	March 6, 2024 / IM Hotel, Makati City
16. FERIDO, MARK A. ATIENZA, RANDY S. RAMIREZ, JOHN ENRIQUE A. TOLENTINO, CELESTINE JOY P. EDUARDO, MARISSA E. BAUZON, PHOEBE HANNAH C. TORRES, ROCHELLELYN L. UBALDE, JOHN PHILLIP U.	Monitoring and Evaluation Workshop	March 12 - 16, 2024 / Jade Hotel, Makati



SUMMARY OF TRAININGS

EMPLOYEE	TRAINING	DATE / VENUE
17. CATINDIG, ANGELITO M.	Ease of Paying Taxes Act - What Accountants Need To Know	March 20, 2024 / Online
18. ATIENZA, RANDY S.	Symposium and Focused Training on New DRTB Regimen	March 25, 2024 / Bayleaf Hotel
19. TOLENTINO, CELESTINE JOY	Integrated HIV Training	April 15-19, 2024 / San Lazaro Hospital
20. KIHOM, HARLEY RONNIEKSON	Ingtegrated rHIVda Proficiency Training	May, 2024 / Baguio City
21. CASTILLO, EANA JOYCE T. TORRES, ROCHELLYN L.	Ingtegrated rHIVda Proficiency Training	May 6 - 11, 2024 / Baguio City
22. TORRES, ROCHELLYN L. CASTILLO, EANA JOYCE	Integrated HIV Training	May 7-11, 2024 / Ating Tahanan, Baguio
23. CABANATAN, MA. LOURDES O.	Maximizing the Use of MS Excel Functionalities in Conducting Auditing Techniques	May 9, 2024 / Online
24. KIHOM, HARLEY RONNIEKSON DE GUZMAN, ALBERTO JR. E. ROWAN, RHANDY R. NUCUM, MARITA I. BALMEO, JULIA ELOISE B. TORRES, ROCHELLYN L. BAUZON, PHOEBE HANNAH DC UBALDE, JOHN PHILLIP C. CASTILLO, EANA JOYCE T. TOLENTINO, CELESTINE JOYCE P.	GCP Workshop & Training	June 10, 2024 / Jade Hotel, Makati



SUMMARY OF TRAININGS

EMPLOYEE	TRAINING	DATE / VENUE
MARIWA, HAIPHA U. JOSON, EVELYN S. DARJUAN, RONALD E. PERENA, MHON ADRIAN G. OCAMPO, CAMILLE C. ILAO, RENZ LOUIE T. DEL AGUA, FLORANCE ETTIENE P. RAMIREZ, JOHN ENRIQUE A.	GCP Workshop & Training	June 10, 2024 / Jade Hotel, Makati
25. MONTON, ROGESELLE B.	International AIDS Conference	July 17 - 27, 2024 / Munic Germany
26. LOBO, SEAN MATTHEW GODSON	Direct Sputum Smear Microscopy	June 17-21, 2024 / Ciudad Christia Resort
27. TORRES, ROCHELLYN L.	Advanced PreP Courses and Updates in HIV Medicine	June 20-21, 2024 / Manila Doctors Hospital
28. NUCUM, MARITA I.	2nd Compensation and Benefits Conference	June 20-21, 2024 / SMX Convention Center, BCG
29 SALVADORA, VIVIENNE GIE E. RULIDA, MARYDITH V. DE GUZMAN, ALBERTO E. JR. CASTILLO, EANA JOYCE T. RAMIREZ, JOHN ENRIQUE A. MARIWA, HAIPHA U.	HIV Counseling to Testing Training	June 25 - 28, 2024 / Jade Hotel, Makati




SUMMARY OF TRAININGS

EMPLOYEE	TRAINING	DATE / VENUE
30. GARCIA, KATHLEEN GRACE T. DE GUZMAN, ALBERTO E. JR. TORREDA, JOEYLYN	Syndromic STI Management Training	July 2 - 5, 2024 / Jade Hotel, Makati
31. KIHOM, HARLEY RONNIEKSON	LEAD to Serve Program Management Course Cohort	July 11, 2024 / Online





TROPICAL DISEASE FOUNDATION, INC.



SERVICES



MOBILE TB SCREENING PROJECT

From August to October 2023, TDF led an active TB case-finding project in 7 barangays across Quezon City (4) and Caloocan City (3).

With support from USAID, FHI360 (TBHIS), and the Department of Health-MMCHD, the project deployed six mobile X-ray vans, each equipped with AI-powered X-ray technology from Radisen and staffed by a team of 9 on-site and remote personnel.



Department of Health –
Metro Manila Center for
Health Development



MOBILE TB SCREENING PROJECT

The mobile units acted as **TB one-stop-shop clinics**, complementing the services of local barangay health centers. Vans were strategically stationed at health centers, schools, playgrounds, and public event venues, attracting thousands of participants for **free TB screening**.



In addition to screenings, the vans—supported by the host barangays—also conducted **health education sessions**, teaching proper handwashing, basic TB information, and promoting local health programs.

Many TB cases were identified and referred for treatment.

The success of this project highlighted new and effective ways of detecting TB early in the community.



MOBILE TB SCREENING PROJECT

OVERVIEW

PARTICIPANTS
(including other
lung diseases) **25,000**

ACTUAL SCREENED
FOR TB **20,042**

NO. OF X-RAY
TB POSITIVE OR
WITH FINDINGS
RELATABLE TO
TB **5,480**



ACCOMPLISHMENTS

SUBMITTED TO
SPUTUM COLLECTION
AND GENE EXPERT
TESTING

380

NO. OF TB GX
POSITIVE

2,268

NO. OF TB GX
NEGATIVE

*some did not submit
sputum for testing

***1,888**

SUBMITTED FOR
TREATMENT

200





iDOTS CLINIC AND iDOTS COORDINATING CENTER (ICC)

TDF offers a public-private DOTS clinic for patients with TB symptoms or suspected tuberculosis. TDF TB-DOTS clinic serves people who live or work in the area, whether they walk in or are referred by doctors from nearby hospitals, clinics, schools, or business establishments.

With the launch of iDOTS (Integrated Delivery of TB Services) Phase II and the Patient-Centered Care approach, all DOTS clinics are now called iDOTS clinics, treating TB patients regardless of drug resistance.

ACCOMPLISHMENTS

NO. OF PRESUMPTIVE
TB CASES SCREENED: **221**

NO. OF PATIENTS
ENROLLED: **53**

NO. OF PATIENTS COMPLETED TREATMENT:

CURED **14**

TREATMENT
COMPLETED: **37**

ONGOING
TREATMENT: **2**

TDF, once a Satellite Treatment Center for DRTB, is now an **iDOTS Coordinating Center (ICC)**, with PBSP staff offering technical support to new iDOTS clinics.

Lab supplies are provided by the Department of Health (DOH) through the Makati City Health Department. Medications are supplied by the DOH, Makati City Health Department, and the Global Fund through the Philippine Business for Social Progress (PBSP).

OVERVIEW

Area of Coverage: Metro Manila

Period of Coverage: August 1, 2023 – July 31, 2024



RADISEN X-RAY FACILITY

Radisen, a developer of artificial intelligence (AI) technology for digital radiography, provided equipment for TDF to establish an x-ray facility on-site.

The facility uses AI technology alongside standard radiographic reading to help Radisen improve their AI system.

OVERVIEW	ACCOMPLISHMENT
<i>Launch Date:</i> September 27, 2021 <i>Area of Coverage:</i> Makati City <i>Period of Coverage:</i> August 1, 2023 – July 31, 2024	CLIENTS ACCOMMODATED FOR THE FISCAL YEAR 199




DSWD DISTRIBUTION OF FINANCIAL/ MEDICAL ASSISTANCE

July 12, 2024






TROPICAL DISEASE FOUNDATION, INC.



PROJECT HIGHLIGHTS





LIFT - TB PH PROJECT

The **Leveraging Innovations for Faster Treatment of Tuberculosis (LIFT-TB)** Project is a joint effort led by TDF and funded by the TB Alliance and Korea International Cooperation Agency (KOICA), with technical support from partners in South Korea and the Netherlands.

It aims to help the Philippines adopt a new, shorter, all-oral treatment called BPaL (Bedaquiline-Pretomanid-Linezolid) for drug-resistant tuberculosis (MDR-TB).

Since 2020, the project has worked with the Department of Health to test the safety and effectiveness of this treatment in 12 sites across 10 regions, in collaboration with the Disease Prevention Control Bureau (DPCB) of the Department of Health (DOH).

98%

Treatment Success Rate among 96 enrolled patients from 12 OR sites in 10 regions

7

Integrated Coordinating Centers (ICCs)

15

iDOTS facilities in 7 regions



LIFT - TB PH PROJECT

The BPaL study showed very high success, proving the treatment is safe and effective for MDR-TB patients.

It officially ended in 2024 with a 98% success rate. Because it's shorter and easier for patients to take, the Department of Health began expanding its use nationwide in 2023.

The project is now wrapping up, with a manuscript submitted to the Journal of Clinical Tuberculosis and Other Mycobacterial Diseases to share lessons from the Philippine experience with the global health community.

It also continues to support the scale-up of new DRTB regimens through capacity building and training. Ultimately, these efforts aim to reach more DRTB patients, offering hope, wider access, and a more patient-centered approach to cure.

12

**OR sites
recognized for
their vital role
in advancing
BPaL
operational
research**

1. The Lung Center of the Philippines (LCP)
2. Dr Jose N Rodriguez Memorial Hospital (DJNMRH)
3. Jose B Lingad Memorial General Hospital (JBL)
4. Ilocos Training and Research Medical Center (ITRMC)
5. Region 1 Medical Center (R1MC)
6. Batangas Medical Center (BatMC)
7. Sorsogon Medical Mission Group Hospital and Health Service Cooperative (SMMGHHSC)
8. Western Visayas Medical Center (WVMC)
9. Eversley Childs Sanitarium (ECS)
10. Zamboanga City Medical Center (ZCMC)
11. Northern Mindanao Medical Center (NMMC)
12. Southern Philippines Medical Center (SPMC)



LIFT - TB PH PROJECT

81
onsite
participants

Including:

- Research Team
- OR site MDs and nurses
- TBMAC representatives
- Regional coordinators/representatives
- DOH-DPCB
- TB People Philippines
- PBSP and project partners

(December, 2023)

76
participants

attended the active Drug Safety Monitoring and Management (aDSM) workshop led by 5 specialists:

1. Ophthalmologist
2. Neurologist
3. Hematologist
4. Hepatologist
5. Cardiologist

to enhance healthcare providers' skills
(December, 2023).

60
participants

joined the World TB Day hybrid symposium featuring the official launch of PeerLINC, including representatives from DOH, Australian Embassy Manila, KOICA, TBA, TBP, LCP, NTRL, PBSP, TDFI, and local government units.

(March, 2024)

4
abstracts

presented at the Union World Conference (International Union Against TB and Lung Diseases) in Paris, France.

(November, 2023)



LIFT - TB PH PROJECT



Recognition ceremony for BPAL OR sites (December 13, 2023)



aDSM strengthening workshop through clinical specialists inputs (December 14-15, 2023)




LIFT - TB PH PROJECT



Symbolic handover of job aids from LIFT-TB Phil Project to DOH-DPCB during the World TB Day Symposium (March 25, 2024)



Monitoring activities in Bicol Region (CHD 5) with the Research Team and TB People Philippines (June 26, 2024)



PHOENIX A5300B

This clinical trial compared the efficacy and safety of 26 weeks of **Delamanid** (DLM) versus 26 weeks of **Isoniazid** (INH) in preventing confirmed or probable active tuberculosis (TB) over a 96-week follow-up period. It focused on high-risk household contacts (HHCs) of adults with multidrug-resistant tuberculosis (MDR-TB).

DRAMATIC-TB TRIAL

A Phase 2, prospective, randomized, partially-blinded trial that evaluated the efficacy and tolerability of a combination treatment including **Bedaquiline**, **Delamanid**, **Levofloxacin**, **Linezolid**, and **Clofazimine** for treating multidrug-resistant tuberculosis (MDR-TB).

A5356

A Phase 2, prospective, randomized, multicenter trial that assessed the efficacy, safety, and tolerability of **two Linezolid** dosing strategies in combination with a short-course regimen for the treatment of drug-resistant pulmonary tuberculosis.

TMC207-C211

A Phase 2, open-label, multicenter, single-arm trial that evaluated the pharmacokinetics, safety, tolerability, and anti-mycobacterial activity of **TMC207** combined with other MDR-TB medications in children and adolescents (from birth to under 18 years) with confirmed or probable pulmonary MDR-TB.




PMDT

Laboratory services including **GeneXpert**, **TB Culture**, and **AFB Microscopy** are provided to support patients under the National TB Program.

VISA SCREENING

TB diagnostic services, including **AFB Microscopy**, **GeneXpert**, **TB Culture**, **DST**, and **IGRA**, are provided to patients of Nationwide Health Systems Aux, Inc. migrating to Canada, Australia, and New Zealand.



TB EQA Performance

PANEL	ROUND					
	1	2	3	4	5	6
AFB Smear	100%	80%	N/A	N/A	N/A	N/A
M. tuberculosisID	100%	100%	N/A	N/A	N/A	N/A
Susceptibilities, MTB	100%	100%	N/A	N/A	N/A	N/A
Susceptibilities,MTB 2 nd line	100%	100%	N/A	N/A	N/A	N/A
GxXDR	100%	100%	100%	N/A	N/A	N/A
MTB/RIF, DNA (GxUltra)	100%	100%	100%	N/A	N/A	N/A
M. tuberculosis, IGRA	N/A	N/A	100%	100%	100%	100%

9,094

A total of 9,094 TB diagnostic tests were conducted, including Microscopy, GeneXpert, TB culture, drug susceptibility testing (DST), and Line Probe Assay.





USAID
FROM THE AMERICAN PEOPLE

EpiC
Meeting Targets and
Maintaining Epidemic Control

In Fiscal Years 2023 and 2024, the Tropical Disease Foundation, Inc. (TDF) made significant progress in HIV prevention, testing, and treatment through the Meeting Targets and Maintaining Epidemic Control (EpiC) project, supported by PEPFAR, USAID, and FHI 360.



VIRAL LOAD TESTING


TDF Laboratory provides HIV Viral Load testing services using GeneXpert HIV Qual cartridges for clients of HIV treatment hubs.

By December 2023, TDF provided VL testing for multiple EpiC sites, significantly improving treatment monitoring.

2,642

clients who have received free Viral Load testing as of July, 2024.






HIV SCREENING

The TDF Laboratory offers HIV screening tests using immunochromatographic assay kits provided by the Department of Health. This service is available to clients of The Primary Clinic.

HIV CONFIRMATORY TESTING

The TDF Laboratory is one of the few private facilities recognized as a **Certified rHIVda Confirmatory Laboratory (CrCL)**. Using the **rapid HIV diagnostic algorithm (rHIVda)**, TDF conducts confirmatory HIV testing for clients who receive reactive results in initial HIV screening, primarily serving areas in Makati and Mandaluyong.

Since April 2024, 138 confirmatory tests have been done, speeding up HIV diagnosis and treatment.





On March 20, 2023, The Primary Clinic by TDF achieved a significant milestone, obtaining its **Certificate of Accreditation as a Primary HIV Care Facility**, reaffirming its commitment to high-quality HIV care. This ensures comprehensive treatment and support for individuals living with HIV.

On July 11, 2023, the clinic launched alongside its newly licensed HIV Testing Laboratory.

**197**

clients enrolled in AntiRetroviral Therapy (ART) with **98%** viral suppression rate





509

clients started on Pre-Exposure Prophylaxis (PrEP) with **99.6%** maintaining an HIV-negative status

2,078



key population clients tested—a **60% increase from last year.**








The Primary Clinic continues to expand accessible, client-focused HIV services, reinforcing its role in the national HIV response.





HIV Laboratory Statistics





2021L001 VACCINE TRIAL

A Phase 3 multinational, randomized, double-blind, placebo-controlled trial that evaluated the efficacy, safety, and immunogenicity of the **inactivated SARS-CoV-2 vaccine (Vero cell)** for the prevention of COVID-19 in healthy adults aged 18 years and older.

JSVCT109 VACCINE TRIAL

A Phase 3 global, multicenter, randomized, double-blind, placebo-controlled trial that evaluated the efficacy, safety, and immunogenicity of a **recombinant COVID-19 vaccine (Sf9 cell-based)** for the prevention of COVID-19 in adults aged 18 years and older.


RT-PCR TESTING FOR BLOOMBERRY

The TDF Laboratory provided RT-PCR Testing services for the detection of **SARS-CoV-2** to employees and partners of Bloomberry Resorts Corporation.

223,276

The TDF COVID-19 Laboratory successfully processed a total of 223,276 samples before the project concluded on September 30, 2023.





LABORATORY INFORMATION SYSTEM

In FY 2023-2024, the TDF TB Laboratory implemented the **DashLabs Information System** to improve data management and streamline workflow. The system supports electronic test ordering, real-time result reporting, and automated data consolidation, aiming to enhance efficiency, reduce errors, and speed up TB diagnostics.

The initial rollout included staff training, system customization to match lab protocols, and a phased integration with existing equipment and reporting systems.

CERTIFICATION AS A RHIVDA CONFIRMATORY LABORATORY



The TDF Laboratory received certification from the Department of Health as a **Rapid HIV Diagnostic Algorithm (rHIVda)** Confirmatory Laboratory, authorizing it to perform confirmatory testing for HIV.

This certification affirms the laboratory's compliance with national quality standards, availability of trained personnel, and capacity to ensure accurate and reliable HIV diagnostic services in support of the country's HIV response.



RENOVATION OF THE TB LABORATORY

The TDF TB Laboratory underwent significant renovations to enhance its functionality, safety, and workflow efficiency.


Key upgrades included **reconfigured laboratory spaces, upgraded ventilation systems, new workstations, and enhanced biosafety infrastructure.**

These improvements aim to boost testing capacity, ensure biosafety compliance, and provide a safer work environment for laboratory personnel.





TROPICAL DISEASE FOUNDATION, INC.

A large, dark blue hexagonal graphic that serves as a background for the title. Inside the hexagon is a blurred photograph of several people, including children, engaged in an activity on a wooden floor. The text 'COMMUNITY ENGAGEMENT' is overlaid in white, bold, sans-serif capital letters.

COMMUNITY ENGAGEMENT

WORLD AIDS DAY 2023


On December 1, 2023, **TDF-EpiC** participated in the global World AIDS Day commemoration with the theme **"Let Communities Lead."** The event focused on the vital role of community-driven efforts in supporting children living with HIV through holistic care and stigma reduction.

In partnership with The Project **Red Ribbon Care Management Foundation, Inc. – Duyan Program**, TDF-EpiC donated essential items to improve shelter services, including an air conditioner, refrigerator, laptops, projector, sound system, sofa set, and six months of food provisions for 76 children with HIV and their guardians.

The event featured song and dance performances, games, and gift-giving, fostering joy and solidarity. At the end, the children's heartfelt messages of gratitude highlighted the power of community support in the fight against HIV/AIDS.



WORLD TB DAY 2024



TDF representatives participated in the World TB Day 2024 commemoration on March 16, 2024 at the Quirino Grandstand in Manila City, with the theme: **"Pilipinas! Para healthy lung, pa-check ka lungs!"**

A major highlight of the event was the Guinness World Record attempt for the largest human lung formation, where **over 5,500 participants** gathered to break the previous record set by India.

Beyond setting a new world record, the event's true success lay in raising awareness about tuberculosis (TB) and challenging the stigma associated with the disease.



INTERNATIONAL AIDS CANDLELIGHT MEMORIAL 2024

The International AIDS Candlelight Memorial (IACM) 2024, themed **"Put People First: Kandila ng Pagkalinga, Liwanag ng Pag-asa,"** focused on raising awareness, supporting HIV advocacy, and honoring those affected by HIV/AIDS.

The event included three major activities:

- free HIV testing for students,
- an HIV advocacy film screening, and
- a meaningful candlelight memorial ceremony.

HIV TESTING



The day began with pop-up HIV testing booths at the University of Makati (UMAK), where **429** students and attendees from nearby local government units participated.

Volunteers from TDF, in collaboration with the Makati Social Hygiene Clinic (SHC), facilitated the testing, provided answers to questions, and shared educational materials.

The high turnout reflected the growing awareness and interest among young people, emphasizing the need for accessible HIV services.

INTERNATIONAL AIDS CANDLELIGHT MEMORIAL 2024

HIV ADVOCACY FILM SCREENING




In the afternoon, three HIV advocacy films—**GULIS**, **Congratulations, DX!**, and **Hanging Out**—were screened, shedding light on the real-life struggles, stigma, and resilience of people living with HIV (PLHIV).

A panel discussion followed, featuring GULIS director Kyle Jumayne Francisco, actor Allen Amoguis from Congratulations, DX!, and Prof. Florabel Esteban of UMAK as the moderator.

The discussion centered on stigma, discrimination, and how inclusive conversations can help shift societal perceptions of HIV.



INTERNATIONAL AIDS CANDLELIGHT MEMORIAL 2024



CANDLELIGHT MEMORIAL CEREMONY



In the evening, participants gathered at the University of Makati Football Field for the candlelight memorial ceremony. The event started with a doxology and choral performances, followed by welcoming remarks from UMAK President Prof. Elyxzur Ramos. Mr. Joshua Young then delivered a keynote speech, emphasizing the crucial role of community involvement in addressing HIV.

INTERNATIONAL AIDS CANDLELIGHT MEMORIAL 2024

CANDLELIGHT MEMORIAL CEREMONY

Recognitions were given to Makati's HIV service providers for their dedication to HIV awareness and treatment.

A solidarity message from the PLHIV community served as a moving testament to the power of compassion, resilience, and collective action in addressing HIV-related challenges.

The event ended with the lighting of LED candles, symbolizing a tribute to those lost to HIV/AIDS and a hope for the future.




Attendees held a moment of silence, reflecting on the ongoing fight against HIV and the importance of prioritizing people in healthcare and advocacy.

IACM 2024 brought together students, advocates, and healthcare professionals, reinforcing TDF's commitment to creating an inclusive environment for those impacted by HIV/AIDS. Through education and remembrance, the event emphasized solidarity, hope, and the need to combat stigma in the HIV response.




INTERNATIONAL AIDS CANDLELIGHT MEMORIAL 2024

May 24, 2024



25TH INTERNATIONAL AIDS SOCIETY (IAS) CONFERENCE




Held in Munich, Germany from July 22 to 26, 2024, the conference brought together global leaders, researchers, healthcare professionals, and advocates to share the latest developments in HIV science, policy, and services.




SPREAD THE LOVE, MAKATI PRIDE EVENT

July 27 2024





TROPICAL DISEASE FOUNDATION, INC.



PARTNERSHIPS



The Tropical Disease Foundation, Inc. (TDF) is dedicated to ensuring equitable healthcare for all, understanding that partnerships are key to strengthening healthcare services and the national HIV response.

TDF works with government agencies, NGOs, healthcare providers, researchers, community advocates, and international partners to address HIV challenges through a collaborative approach.



Communication Planning and Social Media Communication Workshop organized and in partnership with FHI 360 – EpiC Philippines.

These partnerships promote innovation, share knowledge, and improve service delivery, while reducing stigma and discrimination. By uniting efforts, stakeholders expand healthcare access, improve treatment, and create inclusive policies for those affected by HIV.

TDF's collaboration ensures a more effective and compassionate healthcare system for everyone.





TransHealth and Rights Competent Care Training – Organized by FHI 360



Mr. Jaypee Albert Mendoza – Case Manager represented TDF on the most recent Annual Regional Strategic Information and Response Planning Workshop





With The Department of Health – Metro Manila Center for Health Development Annual Program Information Review held in Baguio City last August 2024.



CGCS Mental Health Services

Counseling Services

DoH-Certified HIV Counselors

Ryan C. Villanueva, RGC, LPT Estrella O. Obnamia, RPh, LPT Janella N. Largasas, RPh

UNIVERSITY OF MAKATI
Center for Guidance and Counseling Services

www.facebook.com/UMakCenterforGuidanceServices
www.amsok.org.ph/guidance



The University of Makati and TDFI Collaborative Activities together with the Local Government of City of Makati


PARTNERSHIP WITH NATIONWIDE HEALTHSYSTEMS AUX, INC.

The TDF TB Laboratory partnered with **Nationwide Health Systems Aux, Inc.** to provide comprehensive TB testing for clients applying for visas to Australia, New Zealand, and Canada.


The services include **AFB Microscopy**, **TB Culture**, **Drug Susceptibility Testing (DST)**, **Interferon Gamma Release Assay (IGRA)**, and **GeneXpert testing** to meet visa medical screening requirements.

This collaboration ensures high-quality, timely, and standardized TB diagnostics that align with international immigration health standards.





PARTNERSHIP WITH PULSECLINIC




The TDF Laboratory partnered with **PULSE Clinic** to provide outpatient HIV Viral Load testing. This collaboration supports the clinic's HIV care and treatment program by delivering accurate and timely viral load results, essential for monitoring treatment efficacy and achieving viral suppression among clients.





TROPICAL DISEASE FOUNDATION, INC.



FINANCIAL SUMMARY



REYES TACANDONG & Co.
FIRM PRINCIPLES. WISE SOLUTIONS.

BOA/PRC Accreditation No. 4702
April 14, 2024, valid until June 6, 2026
SEC Registration No. PF201007009

BDO Towers Valero
5741 Paseo de Rosas
Makati City 1226 Philippines
Phone +632 8 962 9100
Fax +632 8 962 9111
Website www.reyestacandong.com

INDEPENDENT AUDITORS' REPORT

The Board of Trustees
Tropical Disease Foundation, Inc.
Philippine Institute of Tuberculosis Building
Amorsolo Street corner Urban Avenue
Barangay Pio Del Pilar, Makati City

Opinion

We have audited the accompanying financial statements of Tropical Disease Foundation, Inc. (the Foundation), a non-stock, non-profit organization, which comprise the statements of assets, liabilities, and fund balances as at July 31, 2024 and 2023, and the statements of revenues and expenses, statements of changes in fund balances, and statements of cash flows for the years then ended, including a summary of significant accounting policies.

In our opinion, the financial statements present fairly, in all material respects, the financial position of the Foundation as at July 31, 2024 and 2023, and its financial performance, and its cash flows for the years then ended in accordance with Philippine Financial Reporting Standard for Small and Medium-sized Entities (PFRS for SME).

Basis for Opinion

We conducted our audits in accordance with Philippine Standards on Auditing (PSA). Our responsibilities under those standards are further described in the *Auditors' Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Foundation in accordance with the Code of Ethics for Professional Accountants in the Philippines (Code of Ethics) together with the ethical requirements that are relevant to the audit of the financial statements in the Philippines, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.


Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with PFRS for SME, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Foundation's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Foundation or to cease operations, or has no realistic alternative but to do so.

THE POWER OF BEING UNDERSTOOD
AUDIT TAX CONSULTING

Reyes Tacandong & Co. is a member of the RSM network. Each member of the RSM network is an independent accounting and consulting firm, and practices in its own right. The RSM network is not itself a separate legal entity of any description in any jurisdiction.



RSM





REYES TACANDONG & Co.
FIRM PRINCIPLES. WISE SOLUTIONS.

- 2 -


Those charged with governance are responsible for overseeing the Foundation's financial reporting process.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with PSA will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, these could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with PSA, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the Foundation's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Foundation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Foundation to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in manner that achieves fair presentation.






REYES TACANDONG & Co.
FIRM PRINCIPLES. WISE SOLUTIONS.


- 3 -

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audits.

REYES TACANDONG & Co.


DARWIN R. JOSUE
Partner

CPA Certificate No. 129765
Tax Identification No. 285-964-191-000
BOA Accreditation No. 4782/P-029; Valid until June 6, 2026
BIR Accreditation No. 08-005144-025-2024
Valid until March 26, 2027
PTR No. 10072434
Issued January 2, 2024, Makati City



November 7, 2024
Makati City, Metro Manila




TROPICAL DISEASE FOUNDATION, INC.
(A Non-stock, Non-profit Organization)

STATEMENTS OF ASSETS, LIABILITIES, AND FUND BALANCES

		July 31	
	Note	2024	2023
ASSETS			
Current Assets			
Cash and cash equivalents	4	P115,504,504	P98,945,706
Receivables	5	34,592,432	15,595,509
Investments in trust funds	6	110,402,547	74,711,527
Other current assets		3,734,924	1,188,137
Total Current Assets		264,234,407	190,440,879
Noncurrent Assets			
Investment property	7	1,083,612	2,084,677
Property and equipment	8	58,716,712	56,875,752
Net retirement plan asset	17	—	252,600
Other noncurrent assets	9	352,194	1,654,653
Total Noncurrent Assets		60,152,518	60,867,682
		P324,386,925	P251,308,561
LIABILITIES AND FUND BALANCES			
Current Liabilities			
Payables	10	P39,535,686	P18,216,544
Income tax payable		3,358,792	2,016,436
Total Current Liabilities		42,894,478	20,232,980
Noncurrent Liabilities			
Net retirement benefit liability	17	1,787,963	—
Deferred tax liability	18	395,889	—
Total Noncurrent Liabilities		2,183,852	—
Total Liabilities		45,078,330	20,232,980
Fund Balances			
General fund	12	219,445,865	172,077,082
Restricted fund		32,373,000	32,373,000
Capital fund		27,448,636	26,587,429
Other comprehensive income		41,094	38,070
Total Fund Balances		279,308,595	231,075,581
		P324,386,925	P251,308,561


See accompanying Notes to Financial Statements.



TROPICAL DISEASE FOUNDATION, INC.
(A Non-stock, Non-profit Organization)
STATEMENTS OF REVENUES AND EXPENSES

	Note	Years Ended July 31	
		2024	2023
SOURCES OF FUNDS	13	₱164,700,028	₱139,698,257
PROGRAM EXPENSES	14	(106,537,899)	(90,660,920)
GENERAL AND ADMINISTRATIVE EXPENSES	15	(21,405,290)	(19,846,985)
OTHER INCOME	16	15,709,972	3,879,678
EXCESS OF REVENUES OVER EXPENSES BEFORE INCOME TAX		₱41,466,811	33,070,030
PROVISION FOR (BENEFIT FROM) INCOME TAX	18		
Current		3,840,932	2,762,954
Deferred		395,889	(52,147)
		4,236,821	2,710,807
EXCESS OF REVENUES OVER EXPENSES		48,229,990	30,359,223
OTHER COMPREHENSIVE INCOME			
Item to be reclassified to profit or loss			
Unrealized gain on fair value changes of investments	9	3,024	3,096
TOTAL COMPREHENSIVE INCOME		₱48,233,014	₱30,362,319

See accompanying Notes to Financial Statements.




TROPICAL DISEASE FOUNDATION, INC.
(A Non-stock, Non-profit Organization)

STATEMENTS OF CHANGES IN FUND BALANCES

		Years Ended July 31	
	Note	2024	2023
GENERAL FUND BALANCE			
Balance at beginning of year		₱172,077,082	₱134,380,572
Excess of revenues over expenses		48,229,990	30,359,223
Transfer from capital fund	8	9,133,044	8,945,745
Transfer to capital fund	8	(9,994,251)	(1,608,458)
Balance at the end of year		219,445,865	172,077,082
RESTRICTED FUND BALANCE			
	12	32,373,000	32,373,000
CAPITAL FUND BALANCE			
Balance at beginning of year		26,587,429	33,924,716
Transfer to general fund	8	(9,133,044)	(8,945,745)
Additions to property and equipment	8	9,994,251	1,608,458
Balance at the end of year		27,448,636	26,587,429
OTHER COMPREHENSIVE INCOME			
<i>Reserve for fair value changes of investments</i>			
Balance at beginning of year		38,070	34,974
Unrealized gain on fair value changes	9	3,024	3,096
Balance at the end of year		41,094	38,070
		₱279,308,595	₱231,075,581


See accompanying Notes to Financial Statements.



TROPICAL DISEASE FOUNDATION, INC.
(A Non-stock, Non-profit Organization)

STATEMENTS OF CASH FLOWS


		Years Ended July 31	
	Notes	2024	2023
CASH FLOWS FROM OPERATING ACTIVITIES			
Excess of revenues over expenses before income tax		₱52,466,811	₱33,070,030
Adjustments for:			
Investment income	6	(10,865,995)	(1,026,220)
Depreciation and amortization	8	9,133,044	8,945,745
Donated laboratory equipment	8	(2,450,718)	—
Retirement benefit expense (income)	17	2,040,563	(2,586,604)
Unrealized foreign exchange loss (gain)	16	(1,563,557)	140,921
Interest income	4	(55,337)	(42,091)
Loss on write-off of receivables	5	—	266,830
Excess of revenues over expenses before working capital changes		48,684,811	38,768,611
Decrease (increase) in:			
Receivables		(18,996,923)	(3,347,073)
Other current assets		(2,546,787)	(759,601)
Other noncurrent assets		37,776	121,324
Increase in payables		21,319,142	5,437,014
Net cash generated from operations		48,498,019	40,220,275
Income tax paid		(2,498,576)	(746,518)
Interest received	4	55,337	42,091
Contributions paid	17	—	(2,000,000)
Net cash provided by operating activities		46,054,780	37,515,848
CASH FLOWS FROM INVESTING ACTIVITIES			
Proceeds from withdrawals of investments in trust funds	6	7,492,985	—
Additions to:			
Investments in trust funds	6	(32,318,010)	(134,169)
Property and equipment	8	(6,275,826)	(1,608,458)
Proceeds from sale of property equipment	8	21,312	—
Advances made to a contractor		—	(1,267,707)
Net cash used in investing activities		(31,079,539)	(3,010,334)
NET INCREASE IN CASH AND CASH EQUIVALENTS		14,975,241	34,505,514
EFFECTS OF FOREIGN EXCHANGE RATE CHANGES ON CASH			
		1,583,557	(140,921)
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR		98,945,706	64,581,113
CASH AND CASH EQUIVALENTS AT END OF YEAR	4	₱115,504,504	₱98,945,706



- 2 -


Years Ended July 31			
	Notes	2024	2023
NONCASH FINANCIAL INFORMATION			
Reclassification from advances to Construction in Progress (CIP)	8	₱1,267,707	₱-
Donated laboratory equipment	8	2,450,718	-
Unrealized gain on fair value changes of investments		3,024	3,096

See accompanying Notes to Financial Statements.





MEET OUR TEAM



EXECUTIVE OFFICERS

JULIUS A. LECCIONES, MD, PHD, DPA
Executive Director

LEILANI C. NAVAL
VP for Program Support

BOARD OF TRUSTEES

DR. RUBEN L. ENCARNACION
Chairman

MANAGEMENT OFFICERS

ANTHONY A. GERONIMO
Laboratory Manager

DR. RHOLINE GEM MARTIN S. VETO
Physician

RHANDY R. ROWAN
Finance Manager

MARITA I. NUCUM
HR Manager

EVELYN S. JOSON
IT Manager

ROGESELLE B. MONTON
Program Manager, EpiC

MEMBERS

DR. CLAVER P. RAMOS

DR. ROBERTA C. ROMERO

DR. CAMILO C. ROA JR.

DR. SOCORRO P. LUPISAN

DR. RAYMUNDO W. LO


DR. MA. IMELDA JOSEFA QUELAPIO

MRS. MERCEDES A. SOLON

ATTY. EDWIN R. ABELLA

ANNUAL REPORT

2023 - 2024



TROPICAL DISEASE FOUNDATION, INC.



+632 8894 074143



www.tdf.org.ph



inquiries@tdf.org.ph



Philippine Institute of Tuberculosis Building
Amorsolo St. corner Urban Ave., Bgy. Pio Del Pilar
Makati City 1230 Philippines